Literature DB >> 12971433

The UNOS Renal Transplant Registry.

J Michael Cecka1.   

Abstract

Based upon data reported to the UNOS Renal Transplant Registry between 1998-2001, the overall one- and projected 10-year graft survival rates for 31,720 cadaveric kidney transplants were 89% and 51%, and for 14,162 living donor transplants they were 95% and 68%, respectively. These results represent improvements of 15% and 13%, respectively, over the 10-year graft survival rates reported for transplants performed during 1987-1989. Repeat kidney transplants accounted for 14% of deceased donor kidney transplants during 1998-2001 and the 3-year graft survival rates were significantly lower for second (77%) and multiply regrafted (73%) than for recipients of a first transplant (79%; p < 0.001). About 1,200 newly defined expanded criteria donor (ECD) kidneys were transplanted each year between 1998-2001. ECD kidneys represented 15% of deceased donor kidneys and yielded a significantly poorer 3-year graft survival rate (68%) and half-life (7.1 years) than kidneys from normal donors over age 5 (81% and 11.9 years; p < 0.001). The graft failure rates (censoring death with a functioning graft) were similar among recipients aged 31-50 and those aged 51-70 comparing both ECD and normal kidneys. The effect of HLA matching on kidney graft survival remains essentially unchanged after 30 years even with remarkable improvements in immunosuppression. Considering transplants performed between 1995-2001, matching for antigens at the HLA-A,-B, and -DR loci resulted in a 16% higher projected 10-year graft survival rate when compared with grafts mismatched for 5-6 HLA antigens (p < 0.001). The 10-year graft survival difference associated with HLA matching in US transplants performed between 1979-1984 and reported to the UCLA Registry before the introduction of cyclosporine was also 16%. The 3-year graft survival rates for zero HLA-DR mismatched normal kidney grafts (excluding ECD kidneys) were 83%, the same as for recipients of 0 HLA-BDR mismatched grafts. Those with one or 2 DR antigens mismatched had significantly poorer outcomes (80% and 77%, p < 0.001). Living donor transplants from offspring to parents and from genetically unrelated donors including spouses increased more than 5-fold since 1994. In 2001 the number of non-spouse unrelated donors surpassed the number of spouses (701 and 616, respectively). Despite the growing number of these HLA-disparate living donor transplants, their 3-year graft survival rates and half-lives remain as high as those for related donors sharing one HLA haplotype with the recipient. Laparoscopic donor nephrectomy now accounts for more than half of living donor surgeries reported to UNOS. There was no difference in graft survival or in early graft function associated with the type of donor surgery for 19,223 living-donor transplants between 1998-2001. Kidney transplants from non-heartbeating donors are beginning to increase and despite a significantly higher incidence of delayed function, 3-year graft survival rate was 79% for transplants between 1998-2001, the same as for conventional brain-dead deceased donor transplants.

Entities:  

Mesh:

Year:  2002        PMID: 12971433

Source DB:  PubMed          Journal:  Clin Transpl        ISSN: 0890-9016


  14 in total

1.  Quality of life after donor nephrectomy.

Authors:  Nick Townell
Journal:  BMJ       Date:  2006-07-29

2.  Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.

Authors:  Masayoshi Okumi; Noritaka Kawada; Naotsugu Ichimaru; Harumi Kitamura; Toyofumi Abe; Ryoichi Imamura; Yasuyuki Kojima; Yukito Kokado; Yoshitaka Isaka; Hiromi Rakugi; Norio Nonomura; Toshiki Moriyama; Shiro Takahara
Journal:  Clin Exp Nephrol       Date:  2011-08-05       Impact factor: 2.801

3.  Early steroid withdrawal in repeat kidney transplantation.

Authors:  Muhammad A Mujtaba; Tim E Taber; William C Goggins; Muhammad S Yaqub; Dennis P Mishler; Martin L Milgrom; Jonathan A Fridell; Andrew Lobashevsky; John A Powelson; Asif A Sharfuddin
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

4.  [Living-donor kidney transplantation].

Authors:  A Mehrabi; H Fonouni; M Golriz; B Schmied; M Tahmasbirad; J Weitz; M W Büchler; M Zeier; J Schmidt
Journal:  Chirurg       Date:  2010-09       Impact factor: 0.955

Review 5.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Immunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity.

Authors:  Satish N Nadig; Suraj K Dixit; Natalie Levey; Scott Esckilsen; Kayla Miller; William Dennis; Carl Atkinson; Ann-Marie Broome
Journal:  RSC Adv       Date:  2015-04-24       Impact factor: 3.361

Review 7.  Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Authors:  Pierre Merville
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Update on kidney transplantation for the urologist.

Authors:  H Albin Gritsch
Journal:  Curr Urol Rep       Date:  2005-02       Impact factor: 2.862

9.  Influence of Donor's Renal Function on the Outcome of Living Kidney Transplantation: 10-Year Follow-up.

Authors:  Hyun Cheol Jeong; Seong Ho Lee; Dae Yul Yang; Sung Yong Kim; Hayoung Kim; Sam Uel Lee; Jeong Won Kim; Won Ki Lee
Journal:  Korean J Urol       Date:  2012-02-20

10.  Identifying Biomarkers from Transcriptomic Signatures in Renal Allograft Biopsies Using Deceased and Living Donors.

Authors:  Bin Yang; Nicolas Sylvius; Jinli Luo; Cheng Yang; Zhanyun Da; Charlottelrm Crotty; Michael L Nicholson
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.